カテゴリ： GlobalData, アイルランド, 企業調査

Shire Plc (SHP)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Shire Plc (SHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012252
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：315
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to serve patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc (SHP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 11
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Shire Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Shire Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16
Shire Plc, Medical Devices Deals, 2011 to YTD 2017 18
Shire Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Shire Plc, Pharmaceuticals & Healthcare, Deal Details 29
Asset Purchase 29
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 29
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 30
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 31
Venture Financing 32
OncoResponse Raises Additional USD3 Million in Series A Financing 32
Promethera Biosciences Raises USD25 Million in Series C Venture Financing 34
Naurex Raises US$25 Million In Venture Financing 36
NeuroPhage Pharma Raises US$17 Million In Series D Financing 38
Lumena Pharma Raises US$45 Million In Series B Financing 39
Foresight Biotherapeutics Raises US$15 Million In Venture Financing 41
Suppremol Raises US$20.6 Million In Series D Financing 42
AesRx Raises US$1.35 Million In Venture Financing 43
Lumena Pharma Raises US$23 Million In Series A Financing 44
NeuroPhage Pharma Raises US$6.4 Million In Series C Financing 45
Ultragenyx Pharma Raises US$75 Million In Series B Financing 46
Naurex Raises US$38 Million In Series B Financing 48
ArmaGen Technologies Raises US$17 Million In Series A Financing 50
bluebird bio Raises US$60 Million In Series D Financing 52
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing 54
NeuroPhage Pharma Raises US$9 Million In Series B-1 Financing 55
FerroKin Biosciences Raises US$3 Million In Venture Financing 56
Lumena Pharma Raises US$2.05 Million In Final Tranche Of Venture Financing 57
Meritage Pharma Raises US$6.5 Million In Venture Financing 58
Chatham Therapeutics Secures US$0.2 Million In Venture Financing 59
AM-Pharma Secures US$39.7 Million In Series D Financing 60
Foresight Biotherapeutics Raises US$2 Million In Venture Financing 62
SARcode Bioscience Secures US$44 Million In Series B Financing Round 63
AesRx Secures An Additional US$0.12 Million In Venture Financing 64
Lotus Tissue Repair Secures US$26 Million In Series A Financing 65
Prexa Pharma Secures An Additional US$3.7 Million In Series B Venture Financing 66
Naurex Secures US$18 Million In Series A Financing Round 67
NeuroPhage Pharma Secures US$12.4 Million In Series B Venture Financing 69
Partnerships 70
Pint Pharma Enters into Licensing Agreement with Dyax 70
Shire and Rani Therapeutics Enter into Agreement 71
Dover Life Sciences Enters into Research Collaboration Agreement with Shire 72
PatientsLikeMe Enters into Agreement with Shire 73
Generium Forms Joint Venture with Shire 74
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 75
Baxalta Enters into Agreement with Precision Biosciences 76
Baxalta Enters into Agreement with Symphogen 77
Novimmune Enters into Research Agreement with Baxalta 78
Shire Enters into Research Agreement with Foundation Fighting Blindness 79
Shire Enters into Research Agreement with Cincinnati Children’s Hospital 80
Cystic Fibrosis Foundation Therapeutics Enters into Research Agreement with Shire 81
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 82
Prasco Labs Enters Into Agreement With Shire For Distribution Of Fosrenol 83
Shire Extends Research Agreement With Santaris Pharma For LNA Drugs 84
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 85
Nimbus Discovery Enters Into Co-Development Agreement With Shire 86
Ethris Enters Into Agreement With Shire Human Genetic Therapies For RNA-Based Therapeutics 87
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 88
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics 89
Shire Enters Into Co-Development Agreement With Boston Children’s Hospital For Pediatric Therapies 90
Shire Enters Into Research Agreement With Fondazione Telethon 91
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 92
ViroPharma Enters Into Co-Marketing Agreement With Prasco Labs For Vancocin 93
arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 94
Prasco Labs Enters Into Co-Marketing Agreement With Shire For Carbatrol 95
Dyax Amends Co-Development Agreement With Defiante Farmaceutica For Kalbitor 96
Shire Enters Into Co-Development Agreement With Shionogi 97
Dyax Expands Its Agreement With Defiante Farmaceutica 98
Dyax Enters Into Research Agreement With Five Prime Therapeutics 99
Prasco Labs Enters Into Distribution Agreement With Shire US Manufacturing 100
Dyax Expands Its Collaboration With Defiante Farmaceutica 101
Licensing Agreements 102
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 102
Shire Enters into Licensing Agreement with Novimmune 103
Shire Enters into Licensing Agreement with Parion Sciences for P-321 104
Neos Therapeutics Enters into Licensing Agreement with Shire 105
Shire Enters into Licensing Agreement with Pfizer 106
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 107
Shire Enters into License agreement with IGAN Biosciences 108
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 109
Premacure Amends Licensing Agreement with Insmed 110
Shire Extends its Licensing Agreement with ArGEN-X 111
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 112
Dyax Enters Into Licensing Agreement With CVie Therapeutics For Kalbitor 114
Dyax Enters Into Licensing Agreement With Novellus Biopharma For Kalbitor 115
Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 116
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 118
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 119
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody 120
GE Healthcare Enters Into Licensing Agreement With Dyax For c-Met Imaging Peptides 121
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 122
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 124
Lumena Pharma Enters Into Licensing Agreement With Pfizer For LUM001 126
ViroPharma Enters Into Licensing Agreement With Intellect Neurosciences For OX1 127
NPS Pharma Enters Into Licensing Agreement With GlaxoSmithKline For SB-423557, SB-423562 And Ronacaleret 128
Dyax Enters Into Licensing Agreement With Kadmon 129
Lotus Tissue Repair Enters Into Licensing Agreement With The University of Southern California 130
ViroPharma Enters Into Licensing Agreement With Halozyme Therapeutics 131
Lumena Pharme Enters Into Licensing Agreement With Satiogen Pharma 132
RaQualia Pharma Enters Into Licensing Agreement With Shire 133
Cerep Enters Into Licensing Agreement With Shire For Bioprint 134
Pervasis Therapeutics Enters Into Licensing Agreement With Massachusetts Institute 135
Equity Offering 137
Shire Plans to Spin Out its Neuroscience Franchise 137
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 138
Baxalta Invests in OncoResponse 139
Dyax Raises USD230 Million in Public Offering of Shares 140
Lumena Pharma Withdrawn IPO 142
Dyax Completes Public Offering Of Shares For US$85 Million 143
Dyax Completes Public Offering Of Shares For US$69 Million 144
NPS Pharma Completes Public Offering Of Shares For US$100 Million 146
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 147
Dyax Completes Private Placement Of Shares For US$20.5 Million 149
NPS Pharma Completes An Underwritten Public Offering For US$113.8 Million 151
Debt Offering 153
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 153
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 155
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 157
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 159
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 161
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 162
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 163
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 164
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 165
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 166
Asset Transactions 167
Lonza to Acquire Mammalian Manufacturing Site from Shire 167
RaNA Therapeutics Acquires MRT Platform from Shire 168
Chronos Therapeutics Acquires Pre-Clinical Programmes from Shire 169
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 170
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 171
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 172
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 173
Organogenesis Acquires Dermagraft From Shire For US$300 Million 175
Acquisition 177
Shire May Acquire Radius Health 177
Shire Acquires Baxalta for USD32 Billion 178
Shire Acquires Dyax 180
Shire Acquires Foresight Biotherapeutics 182
Actelion Rejects Acquisition Offer from Shire 183
Baxter International Acquires SuppreMol for USD225 Million 184
Shire Acquires NPS Pharma for USD5.2 Billion 185
ViroPharma Completes Acquisition of Meritage Pharma for USD245 Million 187
Baxter Acquires AesRx 188
Shire Acquires BIKAM Pharma 189
Shire Acquires Lumena Pharma From RiverVest Venture Partners 190
Shire To Acquire Fibrotech Therapeutics, Biotech Company, For US$75 Million 191
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma 193
AstraZeneca May Acquire Ariad Pharma 194
Shire Completes Acquisition Of Majority Interest In ViroPharma For US$2.7 Billion 196
Shire Acquires Sarcode Bioscience For up to USD675 Million 198
Shire Acquires Premacure, Protein Replacement Therapy Developer 200
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 201
AstraZeneca Reportedly Mulls Acquisition of Shire 202
Shire Acquires Pervasis Therapeutics for USD196 Million 203
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 205
ViroPharma Acquires DuoCort Pharma For US$165 Million 207
Shire Completes Acquisition Of Advanced BioHealing 208
Shire Plc – Key Competitors 210
Shire Plc – Key Employees 211
Shire Plc – Locations And Subsidiaries 212
Head Office 212
Other Locations & Subsidiaries 212
Joint Venture 220
Recent Developments 221
Strategy And Business Planning 221
Apr 27, 2017: Shire opens new HQ office in Dublin City Centre 221
Dec 06, 2016: Planning permission granted for new Shire manufacturing site in Ireland 222
Nov 22, 2016: Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass. 223
Financial Announcements 224
Oct 27, 2017: Shire Reports Strong Earnings Growth in Q3 2017; Reiterates Full Year Guidance 224
Aug 03, 2017: Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance 228
May 02, 2017: Shire delivers strong Q1 2017 revenue growth while advancing late-stage pipeline 232
Feb 16, 2017: Shire Announces Full Year 2016 Results 237
Nov 01, 2016: Shire Reports Q3 2016 Results with Record Revenues and Reiterates Full Year Non GAAP Guidance 240
Aug 02, 2016: Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook 243
Apr 29, 2016: Shire delivers strong Q1 2016 results with double-digit growth in revenue and Non GAAP earnings per ADS 247
Feb 11, 2016: Shire announces Full Year 2015 Results 250
Feb 11, 2016: Shire Delivers Record Full-year Revenue and Strong Double Digit Growth in Non GAAP Diluted Earnings per ADS 254
Corporate Communications 260
Dec 08, 2017: Chief Financial Officer update 260
Dec 08, 2017: Shire: Chief Financial Officer update 261
Dec 01, 2017: Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer 262
Nov 20, 2017: Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of Directors 263
Aug 21, 2017: Shire Director and Senior Management Changes 264
Jan 13, 2017: Shire Joins Illinois Biotechnology Innovation Organization as Leadership Sponsor and Adds Shannon Resetich to the Board 265
Jun 14, 2016: Shire Announces Additional Listing 266
Jun 07, 2016: Shire Announces Directorate change 267
Legal and Regulatory 268
Feb 07, 2017: Shire Responds to US Federal Trade Commission Civil Action 268
Government and Public Interest 269
Jun 15, 2016: Shire Launches 2016 Excellence in ADHD Patient Group Awards 269
Product News 270
09/23/2016: Shire to showcase data on HyQvia during European Society for Immunodeficiencies Biennial Meeting 270
08/09/2016: VONVENDI, The First and Only Recombinant Treatment for Adults Affected by Von Willebrand Disease, Launches in the U.S. 271
08/01/2016: Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System 272
07/21/2016: Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe 273
07/19/2016: Shire presents Update On Vonvendi at International congress of the World Federation of Hemophilia 274
07/19/2016: Shire reinforces commitment in Hematology with robust data presented at international congress of the World Federation of Hemophilia 275
06/23/2017: Shire to present data on SHP648 at ISTH 2017 to advance the standard of care in Hemophilia 276
05/19/2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology 277
05/16/2017: Shire To Present Data on Vyvanse at 2017 Annual Meeting of American Psychiatric Association 278
05/02/2016: Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016) 279
04/26/2017: Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism 280
04/18/2017: Vyvanse (lisdexamfetamine dimesylate) CII Available in a New Chewable Tablet Formulation 281
03/23/2016: CINRYZE (C1 inhibitor [human]) now available in Canada 282
03/03/2016: Baxalta to present on HYQVIA at 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting 283
02/24/2017: First hormone replacement therapy for parathyroid disorder 284
01/06/2017: Xenetic Biosciences Receives $3 Million Milestone Payment from Shire for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia 285
01/03/2017: Xenetic Biosciences to Present at Biotech Showcase 2017 286
Product Approvals 287
Jul 07, 2017: Shire Japan Files Hereditary Angioedema Drug Icatibant 287
Jun 22, 2017: Shire announces EMA validation of VEYVONDI [von Willebrand factor (Recombinant)] Marketing Authorization Application for treatment of von Willebrand disease 288
Dec 27, 2016: Shire announces FDA approval of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] for use in Children and Surgical settings 289
Oct 25, 2016: First And Only Medication Approved In Canada For The Treatment Of Binge Eating Disorder 290
Oct 17, 2016: Shire Announces Update to Vyvanse (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder 291
Jul 11, 2016: FDA Approves Shire’s Xiidra (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease 293
Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) 294
Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions 295
Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP625 for Rare Gastrointestinal Condition 296
May 02, 2016: Baxalta Receives Positive Opinion from Europe’s CHMP for HYQVIA to Treat Pediatric Patients 297
Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets 298
Apr 04, 2016: Baxalta Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan 299
Mar 02, 2016: Baxalta Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A Patients 300
Feb 25, 2016: Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings 301
Feb 10, 2016: Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for children 302
Feb 04, 2016: U.S. FDA Acknowledges Receipt of Resubmission of Shire’s New Drug Application for Lifitegrast for Dry Eye Disease in Adults 303
Jan 27, 2016: Submission of Manufacturing and Marketing Authorization Application for ADHD Medicine S – 877503 304
Jan 25, 2016: Shire Resubmits New Drug Application for Lifitegrast to U.S. FDA 305
Jan 19, 2016: Baxalta Granted EU Marketing Authorization for ONCASPAR (pegaspargase) as a Component of Combination Therapy in Acute Lymphoblastic Leukaemia 306
Clinical Trials 307
Dec 02, 2016: Topline results of Phase 3 investigational study of VONVENDI [von Willebrand factor (Recombinant)] meets primary endpoint effectively controlling bleeding and blood loss during surgical procedures 307
Jul 26, 2016: ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia 308
Jul 26, 2016: Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease 310
May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome 311
Mar 04, 2016: Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A 312
Other Significant Developments 313
Jun 03, 2016: Shire Completes Combination with Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions 313
Feb 09, 2016: Shire Marks 30th Anniversary with Innovative Global Program to Benefit Children with Rare Diseases 314
Appendix 315
Methodology 315
About GlobalData 315
Contact Us 315
Disclaimer 315

List of Tables
Shire Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Shire Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Shire Plc, Deals By Therapy Area, 2011 to YTD 2017 16
Shire Plc, Medical Devices Deals, 2011 to YTD 2017 18
Shire Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 29
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 30
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 31
OncoResponse Raises Additional USD3 Million in Series A Financing 32
Promethera Biosciences Raises USD25 Million in Series C Venture Financing 34
Naurex Raises US$25 Million In Venture Financing 36
NeuroPhage Pharma Raises US$17 Million In Series D Financing 38
Lumena Pharma Raises US$45 Million In Series B Financing 39
Foresight Biotherapeutics Raises US$15 Million In Venture Financing 41
Suppremol Raises US$20.6 Million In Series D Financing 42
AesRx Raises US$1.35 Million In Venture Financing 43
Lumena Pharma Raises US$23 Million In Series A Financing 44
NeuroPhage Pharma Raises US$6.4 Million In Series C Financing 45
Ultragenyx Pharma Raises US$75 Million In Series B Financing 46
Naurex Raises US$38 Million In Series B Financing 48
ArmaGen Technologies Raises US$17 Million In Series A Financing 50
bluebird bio Raises US$60 Million In Series D Financing 52
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing 54
NeuroPhage Pharma Raises US$9 Million In Series B-1 Financing 55
FerroKin Biosciences Raises US$3 Million In Venture Financing 56
Lumena Pharma Raises US$2.05 Million In Final Tranche Of Venture Financing 57
Meritage Pharma Raises US$6.5 Million In Venture Financing 58
Chatham Therapeutics Secures US$0.2 Million In Venture Financing 59
AM-Pharma Secures US$39.7 Million In Series D Financing 60
Foresight Biotherapeutics Raises US$2 Million In Venture Financing 62
SARcode Bioscience Secures US$44 Million In Series B Financing Round 63
AesRx Secures An Additional US$0.12 Million In Venture Financing 64
Lotus Tissue Repair Secures US$26 Million In Series A Financing 65
Prexa Pharma Secures An Additional US$3.7 Million In Series B Venture Financing 66
Naurex Secures US$18 Million In Series A Financing Round 67
NeuroPhage Pharma Secures US$12.4 Million In Series B Venture Financing 69
Pint Pharma Enters into Licensing Agreement with Dyax 70
Shire and Rani Therapeutics Enter into Agreement 71
Dover Life Sciences Enters into Research Collaboration Agreement with Shire 72
PatientsLikeMe Enters into Agreement with Shire 73
Generium Forms Joint Venture with Shire 74
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 75
Baxalta Enters into Agreement with Precision Biosciences 76
Baxalta Enters into Agreement with Symphogen 77
Novimmune Enters into Research Agreement with Baxalta 78
Shire Enters into Research Agreement with Foundation Fighting Blindness 79
Shire Enters into Research Agreement with Cincinnati Children's Hospital 80
Cystic Fibrosis Foundation Therapeutics Enters into Research Agreement with Shire 81
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 82
Prasco Labs Enters Into Agreement With Shire For Distribution Of Fosrenol 83
Shire Extends Research Agreement With Santaris Pharma For LNA Drugs 84
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 85
Nimbus Discovery Enters Into Co-Development Agreement With Shire 86
Ethris Enters Into Agreement With Shire Human Genetic Therapies For RNA-Based Therapeutics 87
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 88
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics 89
Shire Enters Into Co-Development Agreement With Boston Children's Hospital For Pediatric Therapies 90
Shire Enters Into Research Agreement With Fondazione Telethon 91
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 92
ViroPharma Enters Into Co-Marketing Agreement With Prasco Labs For Vancocin 93
arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody 94
Prasco Labs Enters Into Co-Marketing Agreement With Shire For Carbatrol 95
Dyax Amends Co-Development Agreement With Defiante Farmaceutica For Kalbitor 96
Shire Enters Into Co-Development Agreement With Shionogi 97
Dyax Expands Its Agreement With Defiante Farmaceutica 98
Dyax Enters Into Research Agreement With Five Prime Therapeutics 99
Prasco Labs Enters Into Distribution Agreement With Shire US Manufacturing 100
Dyax Expands Its Collaboration With Defiante Farmaceutica 101
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 102
Shire Enters into Licensing Agreement with Novimmune 103
Shire Enters into Licensing Agreement with Parion Sciences for P-321 104
Neos Therapeutics Enters into Licensing Agreement with Shire 105
Shire Enters into Licensing Agreement with Pfizer 106
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 107
Shire Enters into License agreement with IGAN Biosciences 108
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 109
Premacure Amends Licensing Agreement with Insmed 110
Shire Extends its Licensing Agreement with ArGEN-X 111
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 112
Dyax Enters Into Licensing Agreement With CVie Therapeutics For Kalbitor 114
Dyax Enters Into Licensing Agreement With Novellus Biopharma For Kalbitor 115
Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 116
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 118
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 119
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody 120
GE Healthcare Enters Into Licensing Agreement With Dyax For c-Met Imaging Peptides 121
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 122
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 124
Lumena Pharma Enters Into Licensing Agreement With Pfizer For LUM001 126
ViroPharma Enters Into Licensing Agreement With Intellect Neurosciences For OX1 127
NPS Pharma Enters Into Licensing Agreement With GlaxoSmithKline For SB-423557, SB-423562 And Ronacaleret 128
Dyax Enters Into Licensing Agreement With Kadmon 129
Lotus Tissue Repair Enters Into Licensing Agreement With The University of Southern California 130
ViroPharma Enters Into Licensing Agreement With Halozyme Therapeutics 131
Lumena Pharme Enters Into Licensing Agreement With Satiogen Pharma 132
RaQualia Pharma Enters Into Licensing Agreement With Shire 133
Cerep Enters Into Licensing Agreement With Shire For Bioprint 134
Pervasis Therapeutics Enters Into Licensing Agreement With Massachusetts Institute 135
Shire Plans to Spin Out its Neuroscience Franchise 137
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 138
Baxalta Invests in OncoResponse 139
Dyax Raises USD230 Million in Public Offering of Shares 140
Lumena Pharma Withdrawn IPO 142
Dyax Completes Public Offering Of Shares For US$85 Million 143
Dyax Completes Public Offering Of Shares For US$69 Million 144
NPS Pharma Completes Public Offering Of Shares For US$100 Million 146
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 147
Dyax Completes Private Placement Of Shares For US$20.5 Million 149
NPS Pharma Completes An Underwritten Public Offering For US$113.8 Million 151
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 153
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 155
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 157
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 159
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 161
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 162
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 163
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 164
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 165
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 166
Lonza to Acquire Mammalian Manufacturing Site from Shire 167
RaNA Therapeutics Acquires MRT Platform from Shire 168
Chronos Therapeutics Acquires Pre-Clinical Programmes from Shire 169
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 170
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 171
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 172
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 173
Organogenesis Acquires Dermagraft From Shire For US$300 Million 175
Shire May Acquire Radius Health 177
Shire Acquires Baxalta for USD32 Billion 178
Shire Acquires Dyax 180
Shire Acquires Foresight Biotherapeutics 182
Actelion Rejects Acquisition Offer from Shire 183
Baxter International Acquires SuppreMol for USD225 Million 184
Shire Acquires NPS Pharma for USD5.2 Billion 185
ViroPharma Completes Acquisition of Meritage Pharma for USD245 Million 187
Baxter Acquires AesRx 188
Shire Acquires BIKAM Pharma 189
Shire Acquires Lumena Pharma From RiverVest Venture Partners 190
Shire To Acquire Fibrotech Therapeutics, Biotech Company, For US$75 Million 191
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma 193
AstraZeneca May Acquire Ariad Pharma 194
Shire Completes Acquisition Of Majority Interest In ViroPharma For US$2.7 Billion 196
Shire Acquires Sarcode Bioscience For up to USD675 Million 198
Shire Acquires Premacure, Protein Replacement Therapy Developer 200
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 201
AstraZeneca Reportedly Mulls Acquisition of Shire 202
Shire Acquires Pervasis Therapeutics for USD196 Million 203
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 205
ViroPharma Acquires DuoCort Pharma For US$165 Million 207
Shire Completes Acquisition Of Advanced BioHealing 208
Shire Plc, Key Competitors 210
Shire Plc, Key Employees 211
Shire Plc, Other Locations 212
Shire Plc, Subsidiaries 212
Shire Plc, Joint Venture 220

★海外企業調査レポート[Shire Plc (SHP)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • DURECT Corp (DRRX)-医療機器分野：企業M&A・提携分析
    Summary DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s …
  • LED Dental Inc：医療機器：M&Aディール及び事業提携情報
    Summary LED Dental Inc (LED Dental), a subsidiary of LED Medical Diagnostics Inc is a medical device company that offers dental products. The company develops and commercializes detection technologies utilizing tissue fluorescence visualization. Its products include dental imaging systems, CT imagin …
  • CLAAS KGaA mbH：企業の戦略的SWOT分析
    CLAAS KGaA mbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Jack Henry & Associates, Inc.：戦略・SWOT・企業財務分析
    Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report Summary Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Applied Industrial Technologies, Inc.：企業の戦略・SWOT・財務情報
    Applied Industrial Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Applied Industrial Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • American Axle & Manufacturing Holdings, Inc.：企業の戦略・SWOT・財務情報
    American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Central Asia Metals PLC：企業の戦略・SWOT・財務情報
    Central Asia Metals PLC - Strategy, SWOT and Corporate Finance Report Summary Central Asia Metals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • PT. Indonesia Power：企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Cimarex Energy Co (XEC)：石油・ガス：M&Aディール及び事業提携情報
    Summary Cimarex Energy Co (Cimarax) is an independent upstream oil and natural gas company. It carries out the exploration and production of crude oil, natural gas and natural gas liquids (NGLs). The company’s operations are concentrated in two main areas namely the Mid-Continent region consisting o …
  • Netalogue Technologies plc (NTLP)：企業の財務・戦略的SWOT分析
    Summary Netalogue Technologies plc (Netalogue) is a technology company that develops, markets and support e-procurement software systems. The company offers services such as e-commerce solutions, web design, hosting and e-marketing. It solutions include B2B Webstores, B2B/C webstores, B2corp, B2chan …
  • Novan Inc (NOVN)：企業の財務・戦略的SWOT分析
    Novan Inc (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Housing Development & Infrastructure Ltd：企業の戦略・SWOT・財務情報
    Housing Development & Infrastructure Ltd - Strategy, SWOT and Corporate Finance Report Summary Housing Development & Infrastructure Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • NCS Pte. Ltd.：企業の戦略・SWOT・財務情報
    NCS Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary NCS Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Spicers Limited (SRS)：企業の財務・戦略的SWOT分析
    Spicers Limited (SRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • HighPoint Resources Corp (BBG)：企業の財務・戦略的SWOT分析
    Summary HighPoint Resources Corp (HighPoint Resources) formerly Bill Barrett Corp, is an oil and gas company that explores and produces crude oil and natural gas. The company develops and operates oil and natural gas assets located in the Denver-Julesburg Basin of Colorado. Its Denver-Julesburg Basi …
  • Kadant Inc. (KAI)：企業の財務・戦略的SWOT分析
    Kadant Inc. (KAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Apollo Education Group, Inc.：企業の戦略・SWOT・財務情報
    Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Ipsos SA (IPS)：企業の財務・戦略的SWOT分析
    Ipsos SA (IPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • DEME NV：企業の戦略的SWOT分析
    DEME NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Goldin Properties Holdings Ltd：企業の戦略・SWOT・財務情報
    Goldin Properties Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Goldin Properties Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆